Core Viewpoint - The company, Lian Kang Biotechnology Group (00690.HK), has announced a board meeting scheduled for August 28, 2025, to approve its interim financial results for the six months ending June 30, 2025 [1] Group 1 - The board meeting will take place at the company's registered office [1] - The meeting will include the approval of financial performance for both the company and its subsidiaries [1]

聯 康 生 物 科 技 集 團 有 限 公 司* 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就本公佈全部或任 何部分內容或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED * 僅供識別 （於開曼群島註冊成立之有限公司） 聯康生物科技集團有限公司* 主席 梁國龍 香港，二零二五年八月十八日 於 本公 佈日 期 ，董 事 會包 括四 名 執行 董 事梁 國龍 先 生（ 主 席 ）、陳 大偉 先 生（ 副 主 席 ）、趙 志剛先 生（ 行政 總裁 ）及 聞亞磊 博士（ 首 席營 運官 ）；兩 名非執 行董事 邱國 榮先生及張清女士；及三名獨立非執行董事周啓明先生、任啓民先生及馬青山先 生。 （股份代號：0690） 董事會會議的召開日期 茲通 告聯康 生物 科技集 團有限 公司（「本公 司」）將 於二 零二五 年八月 二十八 日（ 星 期四 ）於本公司註冊辦事處舉行董事會（「董事會」）會議，以（ 其中包括 ）批准本公 ...

Group 1 - The core viewpoint of the article highlights the recent stock performance of LianKang Biotechnology Group, which experienced a 5.0% decline, trading at 0.152 yuan per share with a transaction volume of 10.5667 million yuan as of 14:59 on August 12 [1] - LianKang Biotechnology Group focuses on four strategic areas: biopharmaceutical innovation, high-value generic drugs, new materials for medical aesthetics, and CMO (Contract Manufacturing Organization) [1] - The company aims to meet the growing demand for quality healthcare solutions in China, driven by aging population and population growth trends [1] Group 2 - As of the 2024 annual report, LianKang Biotechnology Group reported total revenue of 512 million yuan and a net profit of 76.652 million yuan [2]

Core Viewpoint - The company, LianKang Biotechnology Group, is focused on developing and selling innovative biopharmaceuticals, high-value generics, new medical beauty materials, and CMO services to meet the growing healthcare demands in China [1][2]. Group 1: Company Overview - LianKang Biotechnology Group's stock price increased by 5.0% to 0.168 CNY per share, with a trading volume of 4.28 million CNY as of 14:00 on August 12 [1]. - The company specializes in four strategic areas: biopharmaceutical innovation, high-value generics, new medical beauty materials, and CMO [1]. - The company aims to address the demand for quality healthcare solutions in China, driven by aging population and population growth trends [1]. Group 2: Financial Performance - As of the 2024 annual report, LianKang Biotechnology Group reported total revenue of 512 million CNY and a net profit of 76.65 million CNY [2]. Group 3: Strategic Collaborations - The company actively engages in strategic partnerships with well-known firms, such as Xiangjiang Group, to expand its product portfolio [1]. - LianKang is committed to improving product quality and supply chain security through strategic collaborations and licensing agreements [1].

致：香港交易及結算所有限公司 公司名稱: 聯康生物科技集團有限公司(於開曼群島註冊成立之有限公司) 呈交日期: 2025年8月4日 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 本月底法定/註冊股本總額： HKD 5,000,000,000 第 1 頁 共 11 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00690 | 說明 | 聯康生物科技集團 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | HKD | | 0.01 | HKD | | 5,000,000,000 ...

Group 1 - The core viewpoint of the article highlights the positive market performance of LianKang Biotechnology Group, with a stock price increase of 6.67% to 0.16 CNY per share and a trading volume of 2.55 million CNY as of 11:27 AM on August 4 [1] - LianKang Biotechnology Group focuses on four strategic areas: biopharmaceutical innovation, high-value generic drugs, new materials for medical aesthetics, and CMO (Contract Manufacturing Organization) [1] - The company aims to meet the growing demand for quality healthcare solutions in China, driven by aging population and population growth trends [1] Group 2 - As of the 2024 annual report, LianKang Biotechnology Group reported total revenue of 512 million CNY and a net profit of 76.65 million CNY [2]

Group 1 - The core focus of the company is on the research, production, and sales of innovative biopharmaceuticals, high-value generics, new medical beauty raw materials, and CMO services to meet the demand for quality healthcare solutions in China [1] - The company has formed strategic partnerships with well-known firms such as Xiangjiang Group to expand its product portfolio through collaboration and licensing agreements [1] - As of the latest financial report, the company reported total revenue of 512 million yuan and a net profit of 76.65 million yuan for the year ending 2024 [2] Group 2 - The company's stock price increased by 5.11% to 0.144 yuan per share, with a trading volume of 1.8185 million yuan as of 10:25 AM on August 1 [1] - The company is committed to enhancing product quality and supply chain security to address the healthcare needs arising from China's aging population and growth trends [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 關連交易 — 貸款延期 茲提述本公司日期為二零二四年五月三十一日及二零二四年十一月二十九日有 關預付款及（ 如適用）更替若干貸款的公佈。 於本公佈日期，若干關連人士應付貸款人（ 本公司全資附屬公司 ）的貸款仍未償 還。根據現有條款，貸款將自二零二五年八月五日至二零二五年九月三十日期 間分批到期。 根據延期協議，將（ 其中包括 ）各筆貸款的到期日延期至二零二五年十二月三十 一日。 由於下文所詳述訂約方之間的關係，各借款人均為本公司的關連人士，因此， 延 期 協 議 項 下 擬 進 行 的 交 易 就 上 市 規 則 第 14A 章 而 言 ， 構 成 本 公 司 的 關 連 交 ...

Core Viewpoint - The approval of the listing application for Isavuconazole capsules marks a significant milestone for the company in the antifungal treatment sector, expected to provide effective and safe treatment options for patients with invasive fungal infections by the second half of 2026 [1][2]. Group 1: Product Development and Market Position - Isavuconazole is a new triazole antifungal drug with broad-spectrum antibacterial activity, working by inhibiting the synthesis of ergosterol in fungal cell membranes [1]. - The launch of Isavuconazole capsules will create a synergistic effect with the existing product Voriconazole, further solidifying the company's leadership position in the antifungal market [1]. - The company has established a customized production line for Isavuconazole, ensuring high-quality production and stable supply, which provides a competitive advantage [2]. Group 2: Market Growth and Strategic Planning - The global antifungal drug market is expected to grow significantly, with the Chinese market projected to reach approximately 30 billion RMB by 2030, reflecting a compound annual growth rate of over 10% [2]. - The launch of Isavuconazole capsules will enrich the company's product pipeline and contribute to sales growth, aligning with the increasing demand for innovative and effective therapies [2]. - The company has also received approval for its ophthalmic drug, Diquafosol Sodium Eye Drops, enhancing its ophthalmic product line and providing diverse treatment options for dry eye patients [3].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） * 僅供識別 （股份代號：0690） 自願性公佈 硫酸艾沙康唑膠囊上市申請 已經正式獲中國國家藥品監督管理局(NMPA)受理 香港，二零二五年七月十八日—香港聯康生物科技集團有限公司（「本公司」），連 同其附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，本集團遞交的硫酸艾 沙康唑膠囊的上市申請已正式獲中國國家藥品監督管理局（「NMPA」）受理，受理 號為「CYHS2502599」。這是本集團在抗真菌治療領域取得的重要里程碑，硫酸艾 沙 康 唑 膠 囊預 計 二 零 二 六 年 下 半 年獲 批 上 市 。 為 廣 大 侵襲 性 真 菌 感 染（ 如 侵 襲 性 曲霉病和侵襲性毛霉病 ）患者提 ...